Investors

Investors2018-11-29T05:18:43+00:00

BioVie Non-confidential Company Slide Deck

Please download our non-confidential investor presentation for more specific information about how we intend to address the unmet medical need of acites due to liver cirrhosis.

Recent Press

2911, 2018

BioVie’s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation

BioVie’s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome (HRS) November 28, 2018 LOS ANGELES, CA / ACCESSWIRE / November 28, 2018 / BioVie Inc. (OTCQB: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug designation to [...]

803, 2018

BioVie Responds to Japan Patent Office and Comments on Recent Stock Price Decline

BioVie Responds to Japan Patent Office and Comments on Recent Stock Price Decline March 8, 2018 BEVERLY, Mass., March 07, 2018 (GLOBE NEWSWIRE) — BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it submitted a response to questions raised by the Japanese Patent Office in regards to its application for patent [...]

1112, 2017

BioVie Receives Fast Track Designation for BIV201

BioVie Receives FDA Fast Track Designation for BIV201 for the Treatment of Refractory Ascites Due to Advanced Liver Cirrhosis December 11, 2018 BEVERLY, MA–(Marketwired – December 11, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for BIV201 [...]

811, 2017

BioVie Announces Second Patient Dosed with BIV201 in Phase 2a Clinical Trial

BioVie Announces Second Patient Dosed with BIV201 in Phase 2a Clinical Trial; First Patient Completes 28-day Treatment Regimen November 8, 2017 BEVERLY, MA–(Marketwired – November 08, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, reported today that a second patient has been dosed with the Orphan drug candidate BIV201 (continuous infusion [...]

211, 2017

Mina Sooch Joins BioVie Board of Directors

Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock November 2, 2017 BEVERLY, MA–(Marketwired – November 02, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today welcomed Mina Sooch, a highly seasoned biopharma industry executive, to its Board of Directors as an independent director. In addition, [...]

2510, 2017

Michael Sherman Joins BioVie Board of Directors

Michael Sherman Joins BioVie Board of Directors and Purchases Company Stock October 25, 2017 BEVERLY, MA–(Marketwired – October 25, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today welcomed Michael Sherman, a highly accomplished financial industry executive, to its Board of Directors as an independent director. In addition, Mr. Sherman purchased [...]

2809, 2017

BioVie Announces First Patient Dosed with BIV201 in Phase 2a Clinical Trial for Refractory Ascites due to Liver Cirrhosis

BioVie Announces First Patient Dosed with BIV201 in Phase 2a Clinical Trial for Refractory Ascites due to Liver Cirrhosis September 28, 2017 BEVERLY, MA–(Marketwired – September 28, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, reported today that the first patient has been dosed with BIV201, which is being studied in a Phase [...]

2509, 2017

Rich Wieland Joins BioVie Management Team as Chief Financial Officer

Rich Wieland Joins BioVie Management Team as Chief Financial Officer September 25, 2017 BEVERLY, MA–(Marketwired – September 25, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, is pleased to announce the appointment of R. Richard Wieland II, MBA as the Company’s interim Chief Financial Officer. Mr. Wieland has served as the Chief [...]

1409, 2017

First Patient Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites

First Patient Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites September 14, 2017 BEVERLY, MA–(Marketwired – September 14, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today confirmed enrollment of the first patient in the Company’s mid-stage (Phase 2a) clinical trial of BIV201 for the treatment of patients with [...]

2607, 2017

BioVie Files Patent Application in Japan for BIV201 for the Treatment of Ascites Due to Liver Cirrhosis

BioVie Files Patent Application in Japan for BIV201 for the Treatment of Ascites Due to Liver Cirrhosis July 26, 2017 BEVERLY, MA–(Marketwired – July 26, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, announced today the filing of an application in Japan for patent coverage of the Company’s new drug candidate BIV201 [...]

Forward Looking Statements

This website contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. BioVie has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are BioVie’s need for, and the availability of, substantial capital in the future to fund its operations and research and development. The fact is that BioVie’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in BioVie’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. BioVie undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

This website uses cookies and third party services. Settings Ok

Cookies

This site uses cookies and third party services

Third party embeds

This site allows third-party services to track activity on this site